Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. The company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase III clinical trials for the treatment of growth hormone deficiency. It develops drug candidates that it has licensed from Amunix Operating, Inc. The company was founded in 2008 and is headquartered in Menlo Park, California.
